Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage company, announced that it has reached a consensus with the U.S. Food and Drug Administration (FDA), as to key elements of a crucial Phase 3 clinical program for Simufilam, its lead candidate for the treatment of Alzheimer’s. The...
BrainStorm Cell Therapeutics (NASDAQ: BCLI), a Company focussed on developing autologous cellular therapies for neurodegenerative diseases, has been awarded the Buzz of Bio 2020 in the public therapeutic biotech category. The award recognises the efforts of Brainstorm in the field of neurodegenerative diseases, including progressive...
Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig’s disease is a progressive neurodegenerative disease, characterized by the atrophy of nerve cells in brain and spinal cord, leading to hardening and scarring in the affected region. As the disease progresses, patients gradually lose the functioning of muscles,...
